Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
Michelle K. Greene(Queen's University Belfast), Christopher J. Scott(Queen's University Belfast)
Cited by 19
Related Papers
Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity
|Cell Death and Disease|2014|55
Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature
|Nanoscale|2020|19